Project Grant R41HL180137

The National Heart, Lung, and Blood Institute awarded Fastline LLC $306,383 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test a second-generation one-handed central venous line (CVL) placement device.

Fastline is engineering a simplified CVL insertion device that enables operators to perform all steps of central vein access—needle puncture, aspiration/injection, manometry testing, and guidewire placement—with a single hand while maintaining continuous ultrasound guidance. Current two-handed Seldinger technique procedures prevent continuous visualization after initial needle placement, increasing the risk of mechanical complications such as collapsed lungs, arterial injuries, and venous dissections, which occur in 10–20 percent of CVL placements. The device aims to reduce these complications and broaden access to CVL placement among healthcare professionals with variable experience. Fastline has completed animal studies with a first-generation prototype and now will refine the second-generation design, manufacture prototypes for clinical testing, and empirically measure value in human use by medical practitioners.

The period of performance runs through August 31, 2027. Work is performed in New York, New York.